Interruption of long-term warfarin is not necessary in patients undergoing total hip arthroplasty
| Autor: | Pratheek Chikkalur, Eric Isbister, James Isbister, Shreeram Deshpande, Mohamed Mussa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
030222 orthopedics
medicine.medical_specialty Blood transfusion business.industry medicine.medical_treatment Warfarin 030229 sport sciences Perioperative Arthroplasty Article Discontinuation Surgery 03 medical and health sciences 0302 clinical medicine medicine heterocyclic compounds Orthopedics and Sports Medicine In patient cardiovascular diseases business Hospital stay Total hip arthroplasty medicine.drug |
| Zdroj: | J Orthop |
| ISSN: | 0972-978X |
| Popis: | INTRODUCTION: The management of anticoagulation in patients undergoing arthroplasty remains a challenge. Guidelines for perioperative management of long-term warfarin recommend discontinuation of warfarin preoperatively in low risk patients. We hypothesised that patients who had their warfarin continued during the perioperative period would have shorter hospital stay and no significant increase risk of surgical complications compared to patients who had their warfarin interrupted. METHODS: This was a retrospective review of 20 consecutive patients receiving long-term warfarin who underwent total hip replacement without stopping warfarin. As a control group, we collected same data from 20 age and gender matched patients also on long term warfarin but their warfarin was stopped prior to surgery and restarted postoperatively. RESULTS: There was no significant difference in age, BMI or comorbidities between the 2 groups. There was a statistically significant difference between the two groups in postoperative INR (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect